MediciNova (NASDAQ:MNOV) Given “Buy” Rating at D. Boral Capital
D. Boral Capital reaffirmed their buy rating on shares of MediciNova (NASDAQ:MNOV – Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a $9.00 price target on the biopharmaceutical company’s stock. Separately, StockNews.com began coverage on shares of MediciNova in a report on Wednesday, February 19th. They issued a […]
D. Boral Capital reaffirmed their buy rating on shares of MediciNova (NASDAQ:MNOV – Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a $9.00 price target on the biopharmaceutical company’s stock. Separately, StockNews.com began coverage on shares of MediciNova in a report on Wednesday, February 19th. They issued a […]
